MacroGenics (MGNX) Stock Price, News & Analysis

Company Overview

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: $1.47 to $1.58
• 50-Day Range: $1.06 to $2.00
• 52-Week Range: $0.99 to $5.77
• Volume: 291,851 shs
• Average Volume: 797,171 shs
• Market Capitalization: $93.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.71
• Consensus Rating: Hold

MacroGenics Stock Analysis - MarketRank™

MacroGenics scored higher than 75% of companies evaluated by MarketBeat, and ranked 239th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

MacroGenics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

MacroGenics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MacroGenics are expected to decrease in the coming year, from ($1.06) to ($2.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MacroGenics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MacroGenics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MacroGenics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.79% of the float of MacroGenics has been sold short.

Short Interest Ratio / Days to Cover

MacroGenics has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in MacroGenics has recently increased by 6.37%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MacroGenics does not currently pay a dividend.

Dividend Growth

MacroGenics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.61

Percentage of Shares Shorted

9.79% of the float of MacroGenics has been sold short.

Short Interest Ratio / Days to Cover

MacroGenics has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in MacroGenics has recently increased by 6.37%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.64

News Sentiment

MacroGenics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for MacroGenics this week, compared to 7 articles on an average week.

MarketBeat Follows

2 people have added MacroGenics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MacroGenics insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.00% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MGNX Stock Analysis - Frequently Asked Questions

How have MGNX shares performed this year?

MacroGenics' stock was trading at $3.25 at the beginning of 2025. Since then, MGNX shares have decreased by 54.3% and is now trading at $1.4850.
View the best growth stocks for 2025 here.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) announced its quarterly earnings data on Tuesday, May, 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.04. The biopharmaceutical company earned $13.19 million during the quarter, compared to analyst estimates of $9.59 million. MacroGenics had a negative net margin of 69.07% and a negative trailing twelve-month return on equity of 89.42%.

Who are MacroGenics' major shareholders?

Top institutional shareholders of MacroGenics include Armistice Capital LLC (9.98%), Acadian Asset Management LLC (3.66%), Connor Clark & Lunn Investment Management Ltd. (1.29%) and Jacobs Levy Equity Management Inc. (1.05%). Insiders that own company stock include Target N V Biotech, James Karrels, Ezio Bonvini, Edward Hurwitz and Jeffrey Stuart Peters.
View institutional ownership trends.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include NVIDIA (NVDA), Broadcom (AVGO), Invesco QQQ (QQQ), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MGNX
• CIK: 1125345
• Web: www.macrogenics.com
• Phone: (301) 251-5172
• Fax: 301-251-5321
• Employees: 430
• Year Founded: 2000

Price Target and Rating

• Average Stock Price Target: $5.71
• High Stock Price Target: $14.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +284.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.06 million
• Net Margins: -69.07%
• Pretax Margin: -69.07%
• Return on Equity: -89.42%
• Return on Assets: -38.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.75
• Quick Ratio: 3.69

Sales & Book Value

• Annual Sales: $152.43 million
• Price / Sales: 0.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.46 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 63,090,000
• Free Float: 55,671,000
• Market Cap: $93.69 million
• Optionable: Optionable
• Beta: 2.20